

C004300-Wellness Health Care Services

Plot No. 183 Sushant Lok - II Sector - 56
Gurgaon, 122011
HARYANA, India
Tel : 9999704523
Email : wellness.health247@gmail.com

NAME : MRS KALA GUPTA AGE : 69 Years SEX : Female
LAB REF NO.: **23706527** ACCESSION NO : **0001HG005875**
COLLECTED ON : 03/07/2019 11:00 REGISTERED ON : 03/07/2019 14:59 REPORTED ON: 08/07/2019 10:54
REFERRED BY : SELF

Report Status: Final

Tests	Results	Biological Reference Range	Units
-------	---------	----------------------------	-------

BIOCHEMISTRY

***CA - 15.3. CANCER MARKER. SERUM**

CA - 15.3 **33.4** High <30.0 U/mL

METHOD : CHEMILUMINESCENCE (CLIA)

Interpretation(s)

CA 15.3 is a marker for breast carcinoma.

Use: To monitor response to treatment and for detection of recurrence before symptoms appear.

Significant change is +/- 25%

Increased: In 80% of metastatic breast cancer

May also be increased in Pancreatic, Lung, ovarian, colorectal and liver cancer.

Limitation

CA 15.3 should not be used to diagnose breast cancer, clinical sensitivity is 60% and specificity is 87%

* This test is not covered under any Accreditation scope.

****End Of Report****

Saxena

Dr. Sonal Saxena
MBBS, MD (Pathology)

P Bhatia

Dr. Puneeta Bhatia
MBBS, MD (Biochemistry)

Shishir

Dr. Shishir Kumar
MBBS, MD (Biochemistry)

Cancer Markers CA-15.3 Before
Treatment

C004300-Wellness Health Care Services

Plot No. 183 Sushant Lok - II Sector - 56
Gurgaon, 122011
HARYANA, India
Tel : 9999704523
Email : wellness.health247@gmail.com

NAME : MRS KALA GUPTA AGE : 68 Years SEX : Female
LAB REF NO.: **23300541** ACCESSION NO : **0001HH009441**
COLLECTED ON : 05/08/2019 08:00 REGISTERED ON : 05/08/2019 15:33 REPORTED ON: 05/08/2019 19:33
REFERRED BY : SELF

Report Status: Final

Tests	Results	Biological Reference Range	Units
-------	---------	----------------------------	-------

BIOCHEMISTRY

***CA - 15.3. CANCER MARKER. SERUM**

CA - 15.3 26.9 <30.0 U/mL

METHOD : CHEMILUMINESCENCE (CLIA)

Interpretation(s)

CA 15.3 is a marker for breast carcinoma.

Use:

To monitor response to treatment and for detection of recurrence before symptoms appear.

Significant change is +/- 25%

Increased:

In 80% of metastatic breast cancer

May also be increased in Pancreatic, Lung, ovarian, colorectal and liver cancer.

Limitation

CA 15.3 should not be used to diagnose breast cancer, clinical sensitivity is 60% and specificity is 87%

* This test is not covered under any Accreditation scope.

AMYLASE.SERUM

AMYLASE 67 30-118 U/L

METHOD : ETHYLIDENE BLOCKED-PHPG7

Interpretation(s)

Amylase is a marker of pancreatic disease - elevated in acute pancreatitis, acute exacerbation of chronic pancreatitis; drug induced acute pancreatitis and obstruction of pancreatic duct by stone / carcinoma.

****End Of Report****

Saxena

Dr. Sonal Saxena
MBBS, MD (Pathology)

P Bhatia

Dr. Puneeta Bhatia
MBBS, MD (Biochemistry)

Shishir

Dr. Shishir Kumar
MBBS, MD (Biochemistry)

Cancer Markers CA-15.3 After
Treatment